Advanced search
Publication Cover
Risk Management and Healthcare Policy Volume 16, 2023 - Issue
Submit an article Journal homepage
115
Views
0
CrossRef citations to date
0
Altmetric
ORIGINAL RESEARCH

Drug Pricing of Domestic Anti-PD-L1 Antibody Adebrelimab: Cost-Effectiveness Analysis of the First-Line ES-SCLC Treatment in China

Dongchu Zhou1 Department of Pharmacy, The Second Xiangya Hospital of Central South University, Changsha, People’s Republic of ChinaView further author information
,
Xinrui Dong1 Department of Pharmacy, The Second Xiangya Hospital of Central South University, Changsha, People’s Republic of ChinaView further author information
,
Zhen Zhou2 School of Public Health and Preventive Medicine, Monash University, Melbourne, VIC, AustraliaView further author information
&
Qiao Liu1 Department of Pharmacy, The Second Xiangya Hospital of Central South University, Changsha, People’s Republic of ChinaCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0001-8739-6236View further author information
ORCID Icon
Pages 2521-2529 | Received 07 Sep 2023, Accepted 15 Nov 2023, Published online: 21 Nov 2023

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.